We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Idiopathic Pulmonary Fibrosis
MedXY News
EnglishTag

Idiopathic Pulmonary Fibrosis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Gabapentin for Cough in Idiopathic Pulmonary Fibrosis: Efficacy and Safety Insights from a Randomized Controlled Trial
Clinical Updateschronic coughGabapentin

Gabapentin for Cough in Idiopathic Pulmonary Fibrosis: Efficacy and Safety Insights from a Randomized Controlled Trial

By MedXY|Sep 1, 2026

A randomized, double-blind, placebo-controlled trial demonstrates gabapentin’s significant efficacy and acceptable safety for treating cough in IPF, supporting its clinical use amid limited alternatives.

Deupirfenidone: A New Horizon in Slowing Idiopathic Pulmonary Fibrosis Progression
newsIdiopathic Pulmonary FibrosisDeupirfenidone
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Deupirfenidone: A New Horizon in Slowing Idiopathic Pulmonary Fibrosis Progression

By MedXY|Aug 17, 2026

Deupirfenidone, a deuterated form of pirfenidone, demonstrated efficacy in slowing lung function decline in IPF patients, with a favorable safety profile in a phase 2b trial, offering promise for improved treatment outcomes.

Shared Genetic Foundations of Idiopathic Pulmonary Fibrosis in East Asian and European Populations
newsEast Asian populationsgenetics

Shared Genetic Foundations of Idiopathic Pulmonary Fibrosis in East Asian and European Populations

By MedXY|Jul 11, 2026

Genetic risk loci for idiopathic pulmonary fibrosis (IPF) identified in East Asian populations largely overlap with those found in Europeans, though allele frequencies and effect sizes differ, highlighting shared ancestry and disease mechan

Quantitative CT Progression Thresholds in Idiopathic Pulmonary Fibrosis May Sharpen Annual Monitoring and Risk Stratification
newsfibrosis scoreIdiopathic Pulmonary Fibrosis

Quantitative CT Progression Thresholds in Idiopathic Pulmonary Fibrosis May Sharpen Annual Monitoring and Risk Stratification

By MedXY|Jun 8, 2026

A multicenter study suggests that 1-year quantitative CT fibrosis progression in IPF, particularly a rise of about 4%, is clinically meaningful and prognostically informative for transplant-free survival.

Nerandomilast in Idiopathic Pulmonary Fibrosis: Long-Term Insights from the FIBRONEER-IPF Trial
Internal MedicineChất Ức Chế PDE4BFIBRONEER-IPF

Nerandomilast in Idiopathic Pulmonary Fibrosis: Long-Term Insights from the FIBRONEER-IPF Trial

By MedXY|Mar 31, 2026

An in-depth analysis of the FIBRONEER-IPF trial’s extended follow-up data, evaluating the efficacy and safety of the PDE4B inhibitor nerandomilast in reducing clinical events and mortality in patients with idiopathic pulmonary fibrosi

Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up
Internal MedicineFIBRONEER-IPFIdiopathic Pulmonary Fibrosis

Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up

By MedXY|Mar 28, 2026

Long-term data from the FIBRONEER-IPF trial indicates that while nerandomilast did not significantly impact composite respiratory events, the 18 mg dose suggests a numerical reduction in mortality and maintains a favorable safety profile fo

Nerandomilast in IPF: Does Slowing Lung Function Decline Translate to Improved Survival?
newsFIBRONEER-IPFIdiopathic Pulmonary Fibrosis

Nerandomilast in IPF: Does Slowing Lung Function Decline Translate to Improved Survival?

By MedXY|Mar 16, 2026

This article analyzes the long-term follow-up data from the FIBRONEER-IPF trial, evaluating the efficacy of nerandomilast in idiopathic pulmonary fibrosis. While the drug reduces FVC decline, its impact on composite clinical outcomes remain

Mapping the Preclinical Phase: The Conserved Sequence of Lung Function Decline in Idiopathic Pulmonary Fibrosis
Clinical UpdatesDisease ProgressionDLCO

Mapping the Preclinical Phase: The Conserved Sequence of Lung Function Decline in Idiopathic Pulmonary Fibrosis

By MedXY|Mar 13, 2026

A landmark study identifies a decade-long conserved sequence of disease progression in IPF, revealing that DLCO decline precedes FVC impairment by years, providing a new framework for early diagnosis and clinical trial design.

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
Internal Medicinechronic coughclinical trial

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

By MedXY|Jan 25, 2026

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial
Internal Medicineclinical trialsIdiopathic Pulmonary Fibrosis

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial

By MedXY|Jan 13, 2026

The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.

Dual αvβ6 and αvβ1 Integrin Inhibition Reduces Lung Collagen Deposition in Idiopathic Pulmonary Fibrosis: Insights from a Phase 2 Clinical Trial
newsBexotegrastIdiopathic Pulmonary Fibrosis

Dual αvβ6 and αvβ1 Integrin Inhibition Reduces Lung Collagen Deposition in Idiopathic Pulmonary Fibrosis: Insights from a Phase 2 Clinical Trial

By MedXY|Oct 28, 2025

This phase 2 trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, significantly reduces active type I collagen deposition in IPF lungs, indicating antifibrotic potential and favorable lung remodeling over 12 weeks.

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial
Clinical UpdatesAntifibrotic TherapyBexotegrast

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

By MedXY|Oct 8, 2025

The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.

Rentosertib: The First AI-Discovered TNIK Inhibitor Shows Promise in Idiopathic Pulmonary Fibrosis Phase 2a Trial
Allergy & Immunologyclinical trialIdiopathic Pulmonary Fibrosis

Rentosertib: The First AI-Discovered TNIK Inhibitor Shows Promise in Idiopathic Pulmonary Fibrosis Phase 2a Trial

By MedXY|Oct 5, 2025

Rentosertib, an AI-designed TNIK inhibitor, demonstrated safety and preliminary efficacy in idiopathic pulmonary fibrosis in a randomized phase 2a trial, marking a milestone in AI-driven drug development for progressive lung diseases.

Nerandomilast for Idiopathic and Progressive Pulmonary Fibrosis: Phase 3 Trial Insights
Clinical UpdatesIdiopathic Pulmonary FibrosisNerandomilast

Nerandomilast for Idiopathic and Progressive Pulmonary Fibrosis: Phase 3 Trial Insights

By MedXY|Sep 30, 2025

Phase 3 trials demonstrate that nerandomilast, a selective PDE4B inhibitor, significantly slows lung function decline in idiopathic and progressive pulmonary fibrosis over 52 weeks, with manageable safety profiles.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities